A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?

The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NVO -2.49%), thanks to its type 2 diabetes medicine Ozempic and the Wegovy version approved for weight loss. However, Ozempic and Wegovy are facing stiff competition, notably from Mounjaro and Zepbound, marketed by Novo Nordisk's eternal rival, Eli Lilly. Further, a little-known but highly promising biotech is also looking to challenge Novo Nor ...